
Opinion|Videos|December 22, 2023
Clinical Perspectives in Later Line Therapies for R/R DLBCL
Author(s)Matthew A. Lunning, DO, FACP
Expert shares clinical perspectives and treatment considerations regarding use of later lines of therapy for patients with R/R diffuse large B-cell lymphoma.
Advertisement
Episodes in this series

Advertisement
Latest CME
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Accepts BLA for Ivonescimab in Pretreated EGFR-Mutated NSCLC
2
The Targeted Pulse: New Standards in Myeloma, Melanoma, and More
3
Onvansertib Triplet Shows Dose-Dependent Frontline Benefit in RAS-Mutant Metastatic CRC
4
Pembrolizumab/Lenvatinib Show Efficacy, Safety in Clear Cell Gyn Cancers
5



















